Skip to main content
. 2020 May 27;12(6):1378. doi: 10.3390/cancers12061378

Table 1.

Main characteristics of major PARPi.

Drug Pharmaceutical Company Chemical Formula 2D Structure Catalytic Site EMA Registration
Olaparib/AZD-2281 AstraZeneca C24H23FN4O3 graphic file with name cancers-12-01378-i001.jpg PARP 1, 2 and 3 December 2014
Niraparib/MK-4827 Tesaro/GSK C19H20N4O graphic file with name cancers-12-01378-i002.jpg PARP 1 and 2 November 2017
Rucaparib/AG-014699 Clovis oncology C19H18FN3O graphic file with name cancers-12-01378-i003.jpg PARP 1, 2 and 3 May 2018
Talazoparib/BMN-673 Pfizer C19H14F2N6O graphic file with name cancers-12-01378-i004.jpg PARP 1 and 2
Powerful PARP trapping		 June 2019
Veliparib/ABT-888 AbbVie C13H16N4O graphic file with name cancers-12-01378-i005.jpg PARP 1 and 2
Weakest PARP trapping		 Phase III
Pamiparib/AG-14361 BeiGene C19H20N4O graphic file with name cancers-12-01378-i006.jpg PARP 1 Phase II

PARPi—PARP inhibitors; EMA—European medicines agency; PARP—poly ADP ribose polymerase.